Abstract
Chemotherapy is the backbone of small-cell lung cancer therapy. However, optimal drug combinations and schedules remain to be defined and there is hitherto no world-wide accepted standard regimen. Cisplatin, an alkylating agent with high putative toxicity is currently widely used although its effectiveness in this disease has not been established firmly. We conducted a meta-analysis of published data reporting trials randomizing a cisplatin-containing regimen versus a regimen without this alkylating agent in order to determine possible differences in survival response and toxicity. Nineteen trials have been identified in medical literature (4054 evaluable patients). Ten trials randomized patients to receive a cisplatin-etoposide regimen versus a regimen without any of these two drugs. A subgroup analysis was, therefore, carried out in the nine remaining trials that randomly allocated patients between two regimens differing in the absence or presence of cisplatin, whereas etoposide was given (or not given) in both arms (1579 evaluable patients). The DerSimonian and Laird method was used to estimate the size effects and the Peto and Yusuf method was used in order to generate the odds ratios (OR) of reduction in risk of death and the increase in probability of being responders to chemotherapy. There was no significant difference between the cisplatin-containing regimen and the regimen without this drug when the risk of toxic-death was taken into account with respective probabilities of 3.1 and 2.7% (NS). Patients randomized in a cisplatin-containing regimen had an increase in probability of being responders with an OR of 1.35, 95% confidence interval (CI) of 1.18–1.55;P < 10–5 corresponding to an increase of objective (partial plus complete) response rate from 0.62 to 0.69 (a result taking into account a significant heterogeneity). Patients treated with a cisplatin-containing regimen benefited from a significant reduction of risk of death at 6 months and 1 year with respective OR 0.87, 95% CI 0.75–0.98, P = 0.03, and or 0.80, 95% CI 0.69–0.93, P = 0.002 (no statistical heterogeneity). This corresponded to a significant increase in the probability of survival of 2.6% and 4.4% at 6 months and 1 year respectively. The meta-analysis restricted to the subset of nine trials without etoposide treatment imbalance reached similar conclusions. A cisplatin-containing regimen yields a higher response rate and probability of survival than does a chemotherapy containing others alkylating agents without a perceptible increase in risk of toxic-death. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cerny T, Blair V, Anderson H, Bramwell V and Thatcher N (1987) Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 15: 146–149
Chahinian P, Propert K, Ware J, Zimmer B, Perry M, Hirsch V, Skarin A, Kopel S, Holland J, Comis R and Green M (1989) A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 8: 993–1002
DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188
Eagan R, Lee R, Frytak S, Fleming T, Ingle JN, Creagan ET, Nichols WC, Kvols LK and Coles DT (1981) An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer. Cancer Clin Trials 4: 267–271
Einhorn LH and Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine and bleomycin. Combination chemotherapy in disseminated testicular cancer. Ann Inter Med 87: 293–298
Evans WK, Shepherd FA, Feld D, Osoba D, Dang P and DeBoer G 1985 a) VP-16 and cisplatin as first line therapy for small- cell lung cancer. J Clin Oncol 3: 1471–1477
Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ and De Boer G 1985 b) Etoposide (VP 16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3: 65–71
Evans W, Feld R, Murray N, Willan A, Coy P, Osoba D, Shepherd F, Clark D, Levitt M, MacDonald A, Wilson K, Shelley W and Pater J (1987) Superiority of alternating non-cross-resistant chemotherapy in extensive small-cell lung cancer. A Multicenter, Randomized Clinical Trial by the National Cancer Institute of Canada. Ann Intern Med 107: 451–458
Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S and Intini C (1993) Cisplatin-VP16 alternating with cyclophosphamide–epirubicin versus cyclophosphamide– epirubicin–vincristine in small cell lung cancer. J Chemother 5: 344–347
Feld R, Evans WK, De Boer G, Quirt IC, Shepherd FA, Yeoh JL, Pringle JF, Payne DG, Herman JG and Chamberlain D (1984) Combined modality induction therapy without maintenance chemotherapy for small-cell carcinoma of the lung. J Clin Oncol 2: 294–304
Fukuoka M, Takada M, Negoro S, Kusunoki Y, Matsui K, Ryu S, Sakai N, Takifuji N, Kudoh S and Tamai S (1986) Alternating non-cross resistant chemotherapy for small-cell lung cancer. Jpn J Clin Oncol 16: 261–270
Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855–861
Goodman G, Crowley J, Blasko J, Livingston R, Beck T, Demattia M and Bukowski R (1990) Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol 8: 39–47
Hansen HH and Kristjansen PEG (1991) Chemotherapy of small-cell lung cancer. Eur J Cancer 27: 342–349
Havemann C, Wolf M, Holle R, Gropp C, Drings P, Manke H, Hans K, Schroeder M, Heim M, Victor N, Georgii A, Thomas C, Pflüger K and Bepler G (1987) Alternating versus sequential chemotherapy in small cell lung cancer. A randomised German Multicenter Trial. Cancer 59: 1072–1082
Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M and Phares JC (1984) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 12: 2022–2034
Joss R, Alberto P, Bleher E, Ludwig C, Siegenthaler P, Martinelli G, Sauter C, Schatzmann E and Senn H (1994) Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy of the chest. Ann Oncol 5: 921–928
Kanitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, Rolski J, Schoket Zs, Vukas D, Kaplan E and Eckhardt S (1992) Randomized phase II trial of high-dose 4′-epi-doxorubicin plus cyclophosphamide versus high-dose 4′-epi-doxorubicin plus cisplatin in previously untreated patients with extensive small cell lung cancer. Oncology 49: 327–332
Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA, Kardinal CG, Krook JE, Veeder MH and Wiesenfeld M (1994) Sequencing and schedule effects of cisplatin plus etoposide in small cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 12: 70–76
Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899–909
O’Bryan RM, Crowley JJ, Kim PN, Epstein RB, Neilan B, Coltman CA, W Stuckey WJ and Pazdur R (1990) Comparison of etoposide and cisplatin with bis-chloroethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. Cancer 65: 856–860
Osterlind K, Hansen HH, Hansen M, Dombernowsky P and Andersen PK (1986) Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 4: 1307–1313
Porter LL I.I.I., Johnson DH, Hainsworth JD, Hande KR and Greco A (1985) Cisplatine and etoposide combination chemotherapy for refractory small-cell carcinoma of the lung. Cancer Treat Rep 69: 479–481
Rosenberg B, Van Camp L and Krigas T (1965) Inibition of cell division in Eschericia coli by electrolysis products from a platinum electrode. Nature 205: 698–699
Rossoff AH, Slayton RE and Perlia CP (1976) Preliminary clinical experience with cisdiamminedichloroplatium (II): a new anti-cancer drug. Ann Intern Med 86: 803–812
Roth B, Johnson D, Einhorm L, Schacter L, Cherng N, Cohen H, Crawford J, Randolph J, Goodlow J, Broun G, Omoura G and Greco A (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282–291
Sculier JP, Klastersky J, Libert P, Ravez P, Thiriaux J, Lecomte J, Bureau G, Vandermoten G, Dabouis G, Michel J, Schmerber J, Sergysels R, Becquart D, Mommen P and Paesmans M 1990 a) A randomised study comparing etoposide and vindesine with or without cisplatin as induction therapy for small-cell lung cancer. Ann Oncol 1: 128–133
Sculier JP, Klastersky J, Libert P, Ravez P, Brohee D, Vandermoten G, Michel J; Thiriaux J; Bureau G and Schmerber J 1990 b) A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer. Lung Cancer 6: 110–118
Sculier JP, Paesmans M, Bureau G, Dabaouis G, Libert P, Vandermoten G, Van Cutsem O, Berchier MC, Ries F, Michel J, Sergysels R, Mommen P and Klastersky J (1993) Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European lung cancer working party. J Clin Oncol 11: 1858–1865
Smith A, Anderson G, Chappell G and Bowen R (1991) Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax 46: 172–174
Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, Lamont A and Harper PG (1997) Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89: 577–580
Stewart LA and Parmar MK (1993) Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 341: 418–422
Urban T, Baleyte T, Chastang CL, Jeannin L, Delaval P, Zaegel M, Mornet M, Coetmeur D and Lebeau B (1999) Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. ‘Petites Cellules’ Group. Lung Cancer 25: 105–113
Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, Trovò MG, Nascimben O, Sibau A, Talamini R and Monfardini S (1994) Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomized study. Eur J Cancer 30A: 1474–1478
Wampler G, Heim W, Ellison N, Ahlgren J and Fryer J (1991) Comparison of cyclophosphamide, doxorubicin and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 9: 1438–1445
Wilshaw E and Kroner T (1976) Phase II study of cis-dichlorodiammineplatinum (NSC 119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60: 55–60
Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S, Thiel H, Hruska D, Victor N, Georgii A and Braun C (1987) Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: A Multicenter German randomized Trial. J Clin Oncol 5: 1880–1889
Yusuf S, Cellins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ and Hennekens CH (1985) Intraveinous and intracoranary fibrinolytic therapy in acute myocardial infarction: overview of results in mortality, reinfarction and side effects for 33 randomised clinical trials. Eur Heart J 6: 556–585
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pujol, JL., Carestia & Daurès, JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83, 8–15 (2000). https://doi.org/10.1054/bjoc.2000.1164
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1164
Keywords
This article is cited by
-
A case of alpha-fetoprotein-positive thymic small cell carcinoma: a case report
Surgical Case Reports (2023)
-
Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study
International Journal of Clinical Oncology (2020)
-
Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer
Current Oncology Reports (2020)
-
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Cancer Immunology, Immunotherapy (2020)
-
Primary small cell neuroendocrine carcinoma of adrenal gland
International Cancer Conference Journal (2019)
